These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

487 related items for PubMed ID: 8144942

  • 1. In vivo or in vitro anti-CD3 epsilon chain monoclonal antibody therapy for the prevention of lethal murine graft-versus-host disease across the major histocompatibility barrier in mice.
    Blazar BR, Taylor PA, Vallera DA.
    J Immunol; 1994 Apr 01; 152(7):3665-74. PubMed ID: 8144942
    [Abstract] [Full Text] [Related]

  • 2. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.
    Blazar BR, Taylor PA, Snover DC, Bluestone JA, Vallera DA.
    J Immunol; 1993 Jan 01; 150(1):265-77. PubMed ID: 8417127
    [Abstract] [Full Text] [Related]

  • 3. Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation.
    Johnson BD, McCabe C, Hanke CA, Truitt RL.
    J Immunol; 1995 May 15; 154(10):5542-54. PubMed ID: 7730653
    [Abstract] [Full Text] [Related]

  • 4. Anti-CD3 epsilon F(ab')2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigen.
    Blazar BR, Jenkins MK, Taylor PA, White J, Panoskaltsis-Mortari A, Korngold R, Vallera DA.
    J Immunol; 1997 Dec 15; 159(12):5821-33. PubMed ID: 9550378
    [Abstract] [Full Text] [Related]

  • 5. In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T cell-depleted marrow for the promotion of engraftment.
    Blazar BR, Hirsch R, Gress RE, Carroll SF, Vallera DA.
    J Immunol; 1991 Sep 01; 147(5):1492-503. PubMed ID: 1831826
    [Abstract] [Full Text] [Related]

  • 6. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR, Majewski D, Ozker K, Hanson G.
    J Immunol; 1998 Sep 01; 161(5):2610-9. PubMed ID: 9725263
    [Abstract] [Full Text] [Related]

  • 7. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD, Becker EE, LaBelle JL, Truitt RL.
    J Immunol; 1999 Dec 15; 163(12):6479-87. PubMed ID: 10586039
    [Abstract] [Full Text] [Related]

  • 8. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.
    Blazar BR, Sharpe AH, Taylor PA, Panoskaltsis-Mortari A, Gray GS, Korngold R, Vallera DA.
    J Immunol; 1996 Oct 15; 157(8):3250-9. PubMed ID: 8871619
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers.
    Schlegel PG, Vaysburd M, Chen Y, Butcher EC, Chao NJ.
    J Immunol; 1995 Oct 15; 155(8):3856-65. PubMed ID: 7561092
    [Abstract] [Full Text] [Related]

  • 10. Amelioration of acute graft-versus-host disease and re-establishment of tolerance by short-term treatment with an anti-TCR antibody.
    Maeda T, Eto M, Lin T, Nishimura Y, Kong YY, Nomoto K, Nomoto K.
    J Immunol; 1994 Nov 01; 153(9):4311-20. PubMed ID: 7930630
    [Abstract] [Full Text] [Related]

  • 11. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM, Gorechlad J, Larsen CP, Waller EK.
    Biol Blood Marrow Transplant; 2006 Dec 01; 12(12):1239-49. PubMed ID: 17162205
    [Abstract] [Full Text] [Related]

  • 12. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation.
    Blazar BR, Taylor PA, Fitzsimmons WE, Vallera DA.
    J Immunol; 1994 Aug 15; 153(4):1836-46. PubMed ID: 7519216
    [Abstract] [Full Text] [Related]

  • 13. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
    Berger M, Wettstein PJ, Korngold R.
    Transplantation; 1994 Apr 15; 57(7):1095-102. PubMed ID: 7909395
    [Abstract] [Full Text] [Related]

  • 14. A correlation between conditioning and engraftment in recipients of MHC-mismatched T cell-depleted murine bone marrow transplants.
    Soderling CC, Song CW, Blazar BR, Vallera DA.
    J Immunol; 1985 Aug 15; 135(2):941-6. PubMed ID: 3891856
    [Abstract] [Full Text] [Related]

  • 15. Prevention of lethal graft-versus-host disease in mice by monoclonal antibodies directed to T cells or their subsets. II. Differential effectiveness of IgG2a and IgG2b isotypes of anti-CD3 and anti-CD4 moAb.
    Knulst AC, Noort WA, Tibbe GJ, Benner R, Savelkoul HF.
    Bone Marrow Transplant; 1994 Oct 15; 14(4):535-43. PubMed ID: 7858528
    [Abstract] [Full Text] [Related]

  • 16. Radiotherapy in mice with yttrium-90-labeled anti-Ly1 monoclonal antibody: therapy of established graft-versus-host disease induced across the major histocompatibility barrier.
    Vallera DA, Schmidberger H, Buchsbaum DJ, Everson P, Snover DC, Blazar BR.
    Cancer Res; 1991 Apr 01; 51(7):1891-7. PubMed ID: 2004372
    [Abstract] [Full Text] [Related]

  • 17. Induction of lethal graft-versus-host disease by anti-CD137 monoclonal antibody in mice prone to chronic graft-versus-host disease.
    Kim W, Kim J, Jung D, Kim H, Choi HJ, Cho HR, Kwon B.
    Biol Blood Marrow Transplant; 2009 Mar 01; 15(3):306-14. PubMed ID: 19203721
    [Abstract] [Full Text] [Related]

  • 18. Prevention of lethal graft-vs.-host disease by a single low dose injection of anti-T cell monoclonal antibody to the allograft recipients.
    Knulst AC, Bril-Bazuin C, Benner R.
    Eur J Immunol; 1991 Jan 01; 21(1):103-7. PubMed ID: 1671355
    [Abstract] [Full Text] [Related]

  • 19. Prevention of lethal graft-versus-host disease in mice by monoclonal antibodies directed against T cells or their subsets. I. Evidence for the induction of a state of tolerance based on suppression.
    Knulst AC, Tibbe GJ, Noort WA, Bril-Bazuin C, Benner R, Savelkoul HF.
    Bone Marrow Transplant; 1994 Mar 01; 13(3):293-301. PubMed ID: 8199571
    [Abstract] [Full Text] [Related]

  • 20. A subset of asialo GM1+ cells play a protective role in the occurrence of graft-versus-host disease in mice.
    De Ruysscher D, Sobis H, Vandeputte M, Waer M.
    J Immunol; 1991 Jun 15; 146(12):4065-70. PubMed ID: 1828259
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.